Yong Hui Nies, PhD

Yong Hui Nies, PhD

Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in Frontiers in Neuroscience
Verified
Journal Article
Open access
YPYong Hui Nies, PhD
Yong Hui Nies, PhD
NNNor Haliza Mohamad Najib
Nor Haliza Mohamad Najib
WLWei Ling Lim
Wei Ling Lim
MKMohd Amir Kamaruzzaman
Mohd Amir Kamaruzzaman
MYMohamad Fairuz Yahaya
Mohamad Fairuz Yahaya
STSeong Lin Teoh
Seong Lin Teoh
Parkinson’s disease (PD) is a severely debilitating neurodegenerative disease, affecting the motor system, leading to resting tremor, cogwheel rigidity, bradykinesia, walking and gait difficulties, and postural instability. The severe loss of dopaminergic neurons in the substantia nigra pars compacta causes striatal dopamine deficiency and the presence of Lewy bodies indicates a pathological hallmark of PD. Although the current treatment of PD aims to preserve dopaminergic neurons or to replace dopamine depletion in the brain, it is notable that complete recovery from the disease is yet to be achieved. Given the complexity and multisystem effects of PD, the underlying mechanisms of PD pathogenesis are yet to be elucidated. The advancement of medical technologies has given some insights in understanding the mechanism and potential treatment of PD with a special interest in the role of microRNAs (miRNAs) to unravel the pathophysiology of PD. In PD patients, it was found that striatal brain tissue and dopaminergic neurons from the substantia nigra demonstrated dysregulated miRNAs expression profiles. Hence, dysregulation of miRNAs may contribute to the pathogenesis of PD through modulation of PD-associated gene and protein expression. This review will discuss recent findings on PD-associated miRNAs dysregulation, from the regulation of PD-associated genes, dopaminergic neuron survival, α-synuclein-induced inflammation and circulating miRNAs. The next section of this review also provides an update on the potential uses of miRNAs as diagnostic biomarkers and therapeutic tools for PD.

1 September 2018 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
YPYong Hui Nies, PhD
Yong Hui Nies, PhD
AAAdliah Mhd Ali
Adliah Mhd Ali
NANorlia Abdullah
Norlia Abdullah
FIFarida Islahudin
Farida Islahudin
NSNoraida Mohamed Shah
Noraida Mohamed Shah
A qualitative study among breast cancer patients on chemotherapy: experiences and side effects Yong Hui Nies,1 Adliah Mhd Ali,1 Norlia Abdullah,2 Farida Islahudin,1 Noraida Mohamed Shah1 1Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia; 2Department of Surgery, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia Purpose: The objective of this study was to explore the experiences and side-effects of breast cancer patients on chemotherapy in Malaysia. Participants and methods: Purposive sampling of 36 breast cancer patients who have completed chemotherapy and agreed to participate in semi-structured in-depth interviews. A constant comparative method and thematic analysis were used to analyze the interviews. Results: Data were categorized into six main themes: know nothing of chemotherapy; fear of chemotherapy; patients’ beliefs in alternative treatments; symptom management; staying healthy after chemotherapy; and concerns of patients after chemotherapy. Conclusion: Despite complaints about the bad experiences of their chemotherapy-induced side-effects, these patients still managed to complete the entire course of chemotherapy. Moreover, there is a need for a clinical pharmacy service in the oncology clinic setting in Malaysia in order to provide relevant information to help patients understand the chemotherapy received. Keywords: breast cancer, chemotherapy, clinical pharmacy service, Malaysia, semi-structured interview

13 November 2020 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
NNNor H.M. Najib
Nor H.M. Najib
YPYong Hui Nies, PhD
Yong Hui Nies, PhD
SHSyarifah Aisyah Syed Abd Halim
Syarifah Aisyah Syed Abd Halim
Mohamad Fairuz YahayaMohamad Fairuz Yahaya
Mohamad Fairuz Yahaya
SDSrijit Das
Srijit Das
STSeong Lin Teoh
Seong Lin Teoh
Parkinson’s Disease (PD) is one of the most common neurodegenerative disorders that affects the motor system, and includes cardinal motor symptoms such as resting tremor, cogwheel rigidity, bradykinesia and postural instability. Its prevalence is increasing worldwide due to the increase in life span. Although, two centuries since the first description of the disease, no proper cure with regard to treatment strategies and control of symptoms could be reached. One of the major challenges faced by the researchers is to have a suitable research model. Rodents are the most common PD models used, but no single model can replicate the true nature of PD. In this review, we aim to discuss another animal model, the zebrafish (Danio rerio), which is gaining popularity. Zebrafish brain has all the major structures found in the mammalian brain, with neurotransmitter systems, and it also possesses a functional blood-brain barrier similar to humans. From the perspective of PD research, the zebrafish possesses the ventral diencephalon, which is thought to be homologous to the mammalian substantia nigra. We summarize the various zebrafish models available to study PD, namely chemical-induced and genetic models. The zebrafish can complement the use of other animal models for the mechanistic study of PD and help in the screening of new potential therapeutic compounds.

1 October 2017 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
YPYong Hui Nies, PhD
Yong Hui Nies, PhD
FIFarida Islahudin
Farida Islahudin
WCWei Wen Chong
Wei Wen Chong
NANorlia Abdullah
Norlia Abdullah
FIFuad Ismail
Fuad Ismail
NSNoraida Mohamed Shah
Noraida Mohamed Shah

Purpose:
This study investigated breast cancer patients’ involvement level in the treatment decision-making process and the concordance between patients’ and physician’s perspectives in decision-making. Participants and methods: A cross-sectional study was conducted involving physicians and newly diagnosed breast cancer patients from three public/teaching hospitals in Malaysia. The Control Preference Scale (CPS) was administered to patients and physicians, and the Krantz Health Opinion Survey (KHOS) was completed by the patients alone. Binary logistic regression was used to determine the association between sociodemographic characteristics, the patients’ involvement in treatment decision-making, and patients’ preference for behavioral involvement and information related to their disease. Results: The majority of patients preferred to share decision-making with their physicians (47.5%), while the second largest group preferred being passive (42.6%) and a small number preferred being active (9.8%). However, the physicians perceived that the majority of patients preferred active decision-making (56.9%), followed by those who desired shared decision-making (32.8%), and those who preferred passive decision-making (10.3%). The overall concordance was 26.5% (54 of 204 patient–physician dyads). The median of preference for information score and behavioral involvement score was 4 (interquartile range [IQR] =3–5) and 2 (IQR =2–3), respectively. In univariate analysis, the ethnicity and educational qualification of patients were significantly associated with the patients’ preferred role in the process of treatment decision-making and the patients’ preference for information seeking (p<0.05). However, only educational qualification (p=0.004) was significantly associated with patients’ preference for information seeking in multivariate analysis. Conclusion: Physicians failed to understand patients’ perspectives and preferences in treatment decision-making. The concordance between physicians’ perception and patients’ perception was quite low as the physicians perceived that more than half of the patients were active in treatment decision-making. In actuality, more than half of patients perceived that they shared decision-making with their physicians.

5 May 2017 in Tropical Journal of Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
NSNoraida Mohamed Shah
Noraida Mohamed Shah
BNBilly Lim Tzyy Nan
Billy Lim Tzyy Nan
YPYong Hui Nies, PhD
Yong Hui Nies, PhD
FIFarida Hanim Islahudin
Farida Hanim Islahudin
EHErnieda Mhd Hatah
Ernieda Mhd Hatah
Purpose: To investigate the association between religiosity, perceptions, and knowledge of breast cancer and its treatment among women in Malaysia. Methods: Knowledge and perceptions of breast cancer and its treatment were determined via a questionnaire adapted from previous studies. The Duke Religion Index was used to measure participants’ religiosity. The questionnaires were distributed among women in public areas in Kuala Lumpur. Results: A total of 384 women participated in this study. Non-organisational religious activity (NORA; r = -0.113, p < 0.05) and intrinsic religiosity (IR; r = -0.183, p < 0.01) were significantly negatively correlated with knowledge of breast cancer. NORA (r = 0.115, p < 0.05) and IR (r = 0.229, p < 0.01) were positively, significantly correlated with the perception that patients who underwent treatment for breast cancer can enjoy good quality of life. There was also a significant positive correlation between NORA (r = 0.175, p < 0.05) and IR (r = 0.249, p < 0.01) on the statement that spiritual support improves treatment for breast cancer. IR was the only subscale positively, significantly associated with the perception of choosing breast-conserving surgery as a primary treatment choice (r = -0.111, p < 0.05) and dietary therapies (r = 0.126, p < 0.05) or acupuncture (r = 0.120, p < 0.05) as alternative treatments for breast cancer. Conclusion: Religiosity should be considered in improving women’s knowledge and perceptions of breast cancer and its treatment. Keywords: Breast cancer, Knowledge, Perceptions, Religiosity

20 September 2021 in Entropy
Verified
Journal Article
Open access
PDF file
HNHui Wen Nies
Hui Wen Nies
Mohd Saberi MohamadMohd Saberi Mohamad
Mohd Saberi Mohamad
ZZZalmiyah Zakaria
Zalmiyah Zakaria
WCWeng Howe Chan
Weng Howe Chan
MRMuhammad Akmal Remli
Muhammad Akmal Remli
YPYong Hui Nies, PhD
Yong Hui Nies, PhD
Artificial intelligence in healthcare can potentially identify the probability of contracting a particular disease more accurately. There are five common molecular subtypes of breast cancer: luminal A, luminal B, basal, ERBB2, and normal-like. Previous investigations showed that pathway-based microarray analysis could help in the identification of prognostic markers from gene expressions. For example, directed random walk (DRW) can infer a greater reproducibility power of the pathway activity between two classes of samples with a higher classification accuracy. However, most of the existing methods (including DRW) ignored the characteristics of different cancer subtypes and considered all of the pathways to contribute equally to the analysis. Therefore, an enhanced DRW (eDRW+) is proposed to identify breast cancer prognostic markers from multiclass expression data. An improved weight strategy using one-way ANOVA (F-test) and pathway selection based on the greatest reproducibility power is proposed in eDRW+. The experimental results show that the eDRW+ exceeds other methods in terms of AUC. Besides this, the eDRW+ identifies 294 gene markers and 45 pathway markers from the breast cancer datasets with better AUC. Therefore, the prognostic markers (pathway markers and gene markers) can identify drug targets and look for cancer subtypes with clinically distinct outcomes.